Module 4 Medical Biochemistry Flashcards

Malnutrition and Obesity

  • Definitions and Classifications of Malnutrition

    • Malnutrition: A disease state in which an organism is not receiving the required nutrients to grow and reproduce properly. It encompasses both undernourishment and overnourishment.
    • Undernourishment: Occurs when individuals do not consume enough calories for their bodies to perform basic physiological functions. It is prevalent in developing nations, among specific vulnerable segments in developed countries (children, elderly, strict dieters), and in patients suffering from severe medical trauma, infection, or loss of appetite. Undernourishment depresses the immune system, leaving the body incapable of fighting opportunistic infections.
  • Protein-Energy Malnutrition (PEM) States

Comparison of PEM types: Kwashiorkor and Marasmus

  • Kwashiorkor:

    • Pathophysiology: Severe protein deprivation coupled with significant carbohydrate-based caloric intake.
    • Clinical Presentation: Stunted growth, skin lesions, loss of hair pigment, fatty liver (due to reduced apolipoprotein synthesis for lipid export), decreased serum albumin, and prominent bilateral edema.
    • Physiological Adaptation: Non-adaptive malnutrition state. Muscular wasting and subcutaneous fat loss are minimal because dietary carbohydrates stimulate insulin release, which suppresses lipolysis and muscle proteolysis. It carries a high mortality rate and develops rapidly.
  • Marasmus:

    • Pathophysiology: Severe total caloric deprivation where energy deficit exceeds protein deficit (often occurs in infants when breast milk is replaced by nutrient-poor cereal gruels).

    • Clinical Presentation: Arrested growth, extreme muscle wasting, severe fat depletion, generalized weakness, and anemia. Edema is absent.

    • Physiological Adaptation: Represents an adaptive physiological response to starvation, utilizing body fat and structural protein reserves for basal survival.

    • Overnourishment and Obesity Assessment

  • Obesity: A pathological condition characterized by excessive accumulation of adipose tissue fat, leading to increased early mortality and chronic conditions (Type 2 Diabetes Mellitus, cardiovascular disease, hypertension, stroke, cancer, osteoarthritis, and immune dysfunction).

  • Body Mass Index (BMI): Calculated using imperial or metric units:     BMI=703×weight in pounds(height in inches)2\text{BMI} = 703 \times \frac{\text{weight in pounds}}{(\text{height in inches})^2}

    • Overweight classification: BMI>25 kg/m2\text{BMI} > 25\,kg/m^2
    • Obesity classification: BMI>30 kg/m2\text{BMI} > 30\,kg/m^2
    • Caveat: BMI fails to differentiate between high muscle mass (e.g., in trained athletes) and high adiposity.
  • Waist Circumference: Serves as an indirect measure of visceral fat accumulation, providing a superior risk assessment for metabolic disease:

    • Increased risk thresholds: Waist Circumference>40 inches\text{Waist Circumference} > 40\,\text{inches} (102 cm102\,cm) in men, or Waist Circumference>35 inches\text{Waist Circumference} > 35\,\text{inches} (88 cm88\,cm) in women.

Body Mass Index Chart

  • Anatomic Differences in Fat Deposition

Body shape and location of subcutaneous and visceral fat

  • Android Fat Distribution (Apple Shape):

    • Defined as Waist-to-Hip Ratio (WHR) >0.8> 0.8 in women, or WHR >1.0> 1.0 in men.
    • Characterized by upper-body and visceral fat accumulation surrounding internal abdominal organs.
    • Metabolic Profile: Visceral fat exhibits high metabolic activity and rapid lipolysis, producing high concentrations of free fatty acids (FFAs) and inflammatory cytokines that drain directly into the portal vein to the liver, driving hepatic insulin resistance and dyslipidemia.
  • Gynoid Fat Distribution (Pear Shape):

    • Defined as WHR <0.8< 0.8 in women, or WHR <1.0< 1.0 in men.

    • Characterized by lower-body, subcutaneous fat deposition around the hips, thighs, and buttocks.

    • Metabolic Profile: Composed of larger adipocytes that efficiently store triglycerides (TAGs) with lower rates of lipolysis; FFAs are released into systemic circulation, sparing the liver and presenting a lower risk for chronic metabolic diseases.

    • Adipocyte Dynamics and Etiology of Obesity

  • Adipocyte Hypertrophy vs. Hyperplasia:

    • Modest weight changes in non-obese adults alter adipocyte size (hypertrophy) without changing cell number.
    • Prolonged overnutrition causes adipocytes to reach a maximum physical size limit, triggering the recruitment, differentiation, and proliferation of pre-adipocytes (hyperplasia).
    • Weight loss reduces adipocyte size but does not reduce total cell number. Excess lipid overflow past adipocyte storage capacities leads to ectopic lipid accumulation (e.g., hepatic steatosis).

Adipocyte gain and loss dynamics

  • Set Point Hypothesis & Polygenic Influences:
    • Set-point hypothesis proposes an internal biological control mechanism returning body weight to a baseline set point following forced overeating or underfeeding.

Body weight set point regulation

- Monogenic mutations causing obesity are rare. Obesity is polygenic, shaped by complex interactions between inherited genetic predispositions (shown in adoption and twin studies) and modern obesogenic environments.
  • Hormonal Regulators of Energy Balance

    • Leptin: Peptide hormone secreted by adipocytes proportional to fat mass. Acts on the hypothalamus to induce satiety and enhance energy expenditure. Obese individuals display elevated circulating leptin levels alongside central leptin resistance.
    • Insulin: Pancreatic hormone elevated postprandially; acts centrally to suppress appetite and signal adequate peripheral energy stores. Obese individuals display hyperinsulinemia and peripheral/central insulin resistance.
    • Ghrelin: Orexigenic peptide secreted primarily by the stomach during fasting. Acts on the brain to stimulate hunger. Plasma ghrelin levels decline postprandially and show an inverse correlation with BMI (circulating ghrelin is lower in obese individuals than in lean controls).
  • Metabolic Complications and Interventions

    • Metabolic Syndrome: A cluster of at least three concurrent abnormalities: abdominal obesity (waist >40 inches> 40\,\text{inches} men, >35 inches> 35\,\text{inches} women), hyperglycemia (fasting blood glucose >126 mg/dL> 126\,mg/dL), dyslipidemia (elevated TAGs, low HDL), and systemic hypertension. Drives chronic systemic inflammation and reduces plasma adiponectin.
    • Non-Alcoholic Fatty Liver Disease (NAFLD): Ectopic TAG deposition in hepatocytes (hepatic steatosis), capable of progressing to liver cirrhosis and hepatocellular carcinoma.
    • Weight Loss Interventions:
    • Target: A ∼10%\sim 10\% reduction in body weight yields significant metabolic benefits.
    • Indications: Indicated for individuals with BMI>30 kg/m2\text{BMI} > 30\,kg/m^2, or BMI>27 kg/m2\text{BMI} > 27\,kg/m^2 with obesity-related comorbidities.
    • Caloric Restriction & Exercise: Caloric restriction alone induces a physiological drop in basal metabolic rate. Physical activity increases cardiopulmonary fitness, improves blood glucose, and aids long-term maintenance.
    • Pharmacotherapy: GLP-1 receptor agonists stimulate glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and promote central satiety, yielding up to ∼30%\sim 30\% weight loss.
    • Bariatric Surgery: Includes Roux-en-Y gastric bypass and adjustable gastric banding. Reserved for patients with BMI>35 kg/m2\text{BMI} > 35\,kg/m^2 who failed conservative therapies. Produces immediate metabolic improvements in blood glucose and blood pressure.

Principles of Macronutrients and Energy Balance

  • Nutritional Reference Intake Framework

    • Dietary Reference Intakes (DRIs): Formulated by the Food and Nutrition Board of the National Academy of Sciences to establish daily nutrient intake thresholds based on age, biological sex, and physiological state.
    • Estimated Average Requirement (EAR): Daily intake meeting the nutrient requirements of 50%50\% of healthy individuals in a given life stage.
    • Recommended Dietary Allowance (RDA): Average daily intake sufficient to meet the nutrient requirements of nearly all (97–98%97\text{--}98\%) healthy individuals (RDA>EAR\text{RDA} > \text{EAR}).
    • Adequate Intake (AI): Estimated intake level used when experimental evidence is insufficient to establish an EAR or RDA.
    • Tolerable Upper Intake Level (UL): Maximum daily intake unlikely to pose a risk of adverse health effects.
    • Daily Values (DVs): Simplified intake figures printed on food labels, based on a reference 2000 kcal/day2000\,kcal/day adult diet.
  • Energetics and Energy Requirements

    • Caloric Values of Dietary Substrates:
    • Carbohydrates: 4 kcal/g4\,kcal/g
    • Proteins: 4 kcal/g4\,kcal/g
    • Fats: 9 kcal/g9\,kcal/g
    • Ethanol: 7 kcal/g7\,kcal/g

Macronutrient caloric density

  • Total Energy Expenditure (TEE): Composed of three primary variables:
    • Resting Metabolic Rate (RMR): Energy required for basal involuntary physiological functions (respiration, ion pumping, circulation). Accounts for ∼60%\sim 60\% of TEE (∼1700 kcal/day\sim 1700\,kcal/day for men, ∼1300 kcal/day\sim 1300\,kcal/day for women).
    • Thermic Effect of Food (TEF): Metabolic energy spent digesting, absorbing, and processing nutrients. Accounts for 10–15%10\text{--}15\% of TEE (proteins and complex carbohydrates demand higher TEF than lipids).
    • Physical Activity: Highly variable fraction based on duration and physical exertion.
  • Acceptable Macronutrient Distribution Ranges (AMDR):
    • Carbohydrates: 45–65%45\text{--}65\% of total daily calories.
    • Fats: 20–35%20\text{--}35\% of total daily calories.
    • Proteins: 10–35%10\text{--}35\% of total daily calories.

Components of Total Energy Expenditure

  • Carbohydrates and Fiber

    • Available Carbohydrates: Monosaccharides, disaccharides, and digestible polysaccharides (starches, glycogen) broken down to monosaccharides for cellular absorption. Chronic intake of simple sugars leads to glycemic spikes and metabolic dysfunction.
    • Unavailable Carbohydrates (Dietary Fiber): Non-digestible plant carbohydrates:
    • Soluble Fiber (e.g., pectins): Form viscous gels in the colon; delay gastric emptying, increase satiety, blunt postprandial glucose spikes, and lower serum cholesterol by binding bile acids.
    • Insoluble Fiber (e.g., cellulose): Add intestinal bulk, stimulate peristalsis, accelerate transit time, and decrease fecal exposure to potential carcinogens.
    • Glycemic Index (GI) and Glycemic Load (GL):
    • Glycemic Index (GI): Measures the relative postprandial rise in blood glucose produced by a fixed amount (50 g50\,g) of digestible carbohydrates from a test food compared to a pure glucose standard (GI=100\text{GI} = 100):       GI=AUCtest foodAUCglucose×100\text{GI} = \frac{\text{AUC}_{\text{test food}}}{\text{AUC}_{\text{glucose}}} \times 100
      • High GI: >70> 70 (e.g., white rice, baked potatoes, donuts).
      • Low GI: <55< 55 (e.g., lentils, apples, whole grains).
    • Glycemic Load (GL): Incorporates realistic serving sizes by multiplying GI by the actual quantity of available carbohydrate per serving:       GL=GI×carbohydrates per serving (g)100\text{GL} = \frac{\text{GI} \times \text{carbohydrates per serving (g)}}{100}
  • Dietary Proteins and Nitrogen Balance

    • Protein Dynamics: Amino acids derived from dietary intake and tissue turnover enter a systemic amino acid pool. Proteins are not stored in dedicated energy-storage molecules.
    • Nitrogen Balance:
    • Positive Nitrogen Balance: Nitrogen intake exceeds excretion. Occurs during periods of tissue synthesis and anabolism (growth, pregnancy, lactation, recovery from trauma).
    • Negative Nitrogen Balance: Nitrogen excretion exceeds intake. Occurs during tissue catabolism, protein malnutrition, thermal injury, starvation, or severe infection.
    • Protein Quality: High-quality (complete) proteins (e.g., animal products, eggs, milk, meat) contain all 9 essential amino acids in proportions required for human tissue synthesis. Plant proteins are frequently incomplete (e.g., beans are rich in lysine but deficient in methionine; wheat is rich in methionine but deficient in lysine). Combining complementary plant foods (e.g., beans and wheat) yields a complete amino acid profile.
    • Protein Intake: Recommended allowance for healthy adults is 0.8 g/kg body weight/day0.8\,g/kg\,\text{body weight/day}.
  • Dietary Lipids and Essential Fatty Acids

    • Essential Fatty Acids: Cannot be synthesized de novo due to lack of human enzymes capable of inserting double bonds past position carbon-9. Must be provided in the diet:
    • Linolenic Acid (18:3ω−318:3\omega-3): Precursor to omega-3 fatty acids EPA and DHA; found in flaxseed, soy, canola, and walnut oils.
    • Linoleic Acid (18:2ω−618:2\omega-6): Precursor to arachidonic acid (20:4ω−620:4\omega-6); found in vegetable oils, nuts, and seeds.
    • Essential fatty acids serve as structural lipid bilayer components and precursors for eicosanoids (prostaglandins, leukotrienes, thromboxanes).
    • Lipid Structural Variants:
    • Cis-Unsaturated Fats: Naturally occurring, liquid at room temperature; lower LDL cholesterol and reduce cardiovascular risk.
    • Trans-Unsaturated Fats: Produced industrially via partial hydrogenation; elevate LDL cholesterol, reduce HDL cholesterol, induce vascular inflammation, and increase coronary heart disease risk.
    • Saturated Fats: Possess no double bonds, solid at room temperature; excessive intake raises serum LDL cholesterol.

Water-Soluble Vitamins

  • General Properties
    • Comprise Vitamin C and the eight B-complex vitamins. Non-caloric micronutrients required in milligram or microgram amounts.
    • Soluble in aqueous environments; readily absorbed and rapidly excreted in urine when plasma levels exceed renal thresholds.
    • With the critical exception of Vitamin B12B_{12}, water-soluble vitamins are not stored in significant quantities in body tissues; dietary deficiencies develop rapidly within days to weeks.
    • Function primarily as essential coenzymes or prosthetic groups in metabolic pathways.

Overview of Vitamin Hierarchy

  • Vitamin B1B_1 (Thiamine)
    • Active Coenzyme Form: Thiamine Pyrophosphate (TPP), formed by transfer of a pyrophosphate group from ATP to thiamine.
    • Biological Function: Coenzyme for transketolase in the pentose phosphate pathway, pyruvate dehydrogenase complex, and α\alpha-ketoglutarate dehydrogenase complex in the TCA cycle.

TPP Coenzyme Functions

  • Deficiency Disorders:

    • Beriberi: Seen in populations consuming diets based on polished rice. Dry Beriberi presents with symmetric peripheral neuropathy, muscle wasting, and sensory deficits. Wet Beriberi presents with high-output heart failure, tachycardia, cardiomegaly, and peripheral edema.

    • Wernicke-Korsakoff Syndrome: Associated with chronic alcohol abuse due to impaired intestinal thiamine absorption. Characterized by the triad of ophthalmoplegia/nystagmus, ataxia, and severe memory impairment/confabulation.

    • Vitamin B2B_2 (Riboflavin)

  • Active Coenzyme Forms: Flavin Mononucleotide (FMN) and Flavin Adenine Dinucleotide (FAD).

  • Biological Function: Serve as tightly bound prosthetic groups for oxidation-reduction enzymes involved in macronutrient metabolism and electron transport (Complex I uses FMN; Complex II uses FAD).

  • Deficiency Symptoms: Characterized by mucocutaneous inflammatory lesions: scaly dermatitis, angular cheilitis (fissuring at the corners of the mouth), glossitis (magenta/purplish tongue), pharyngeal edema, and cheilosis.

Conversion of Riboflavin to FMN and FAD

  • Vitamin B3B_3 (Niacin / Nicotinic Acid / Nicotinamide)
    • Active Coenzyme Forms: Nicotinamide Adenine Dinucleotide (NAD+\text{NAD}^+) and Nicotinamide Adenine Dinucleotide Phosphate (NADP+\text{NADP}^+).
    • Biological Function: Electron carriers in catabolic (NAD+\text{NAD}^+) and anabolic/antioxidant (NADP+\text{NADP}^+) redox reactions.
    • Endogenous Synthesis: Humans convert the essential amino acid tryptophan into niacin: 60 mg60\,mg of dietary tryptophan produces 1 mg1\,mg of niacin.

Conversion of Niacin and Tryptophan to NAD+ and NADP+

  • Pellagra: Severe niacin deficiency disease characterized by the classic 3 (or 4) Ds:

    1. Dermatitis: Photosensitive, dark, scaly cutaneous eruptions.
    2. Diarrhea: Severe gastrointestinal mucosal inflammation.
    3. Dementia: Central nervous system disorientation, encephalopathy, and memory loss.
    4. Death: If left untreated.
  • Toxicity: Tolerable Upper Intake Level is set at 35 mg/day35\,mg/day. High pharmacological doses used to treat hyperlipidemia cause cutaneous vasodilation (flushing) and prostaglandin-mediated pruritus.

    • Vitamin B5B_5 (Pantothenic Acid)
  • Active Coenzyme Form: Component of Coenzyme A (CoA) and the Acyl Carrier Protein (ACP) domain of fatty acid synthase.

  • Biological Function: Transfer of acyl groups during carbohydrate oxidation, fatty acid synthesis/β\beta-oxidation, and amino acid catabolism.

  • Deficiency: Exceptionally rare due to its ubiquitous presence across food sources (AI=5 mg/day\text{AI} = 5\,mg/day).

    • Vitamin B6B_6 (Pyridoxine, Pyridoxal, Pyridoxamine)
  • Active Coenzyme Form: Pyridoxal Phosphate (PLP).

  • Biological Function: Coenzyme for transamination, deamination, decarboxylation, and condensation reactions in amino acid metabolism. Required for conversion of tryptophan to niacin, glycogen breakdown via glycogen phosphorylase, neurotransmitter synthesis (dopamine, serotonin, GABA), and δ\delta-aminolevulinic acid (ALA) synthase in heme biosynthesis.

  • Deficiency: Reported as the most common B-vitamin deficiency in the US (∼10.5%\sim 10.5\% prevalence). Manifests as microcytic hypochromic anemia (due to impaired heme synthesis), cheilosis, glossitis, peripheral neuropathy, and seizures. Isoniazid (anti-tuberculosis drug) forms an inactive hydrazone complex with PLP, inducing severe deficiency unless co-supplemented.

  • Toxicity: The only water-soluble vitamin with profound neurotoxicity at elevated supplement doses. UL=100 mg/day\text{UL} = 100\,mg/day (vs. RDA=1.3 mg/day\text{RDA} = 1.3\,mg/day). Causes irreversible sensory neuropathy, ataxia, and loss of proprioception.

    • Vitamin B7B_7 (Biotin)
  • Active Form: Covalently bound prosthetic group attached to lysine residues of carboxylase enzymes.

  • Biological Function: Carrier of activated carbon dioxide (CO2\text{CO}_2) in carboxylation reactions (pyruvate carboxylase, acetyl-CoA carboxylase, propionyl-CoA carboxylase).

  • Deficiency: Rare due to intestinal bacterial synthesis (AI=30 μg/day\text{AI} = 30\,\mu g/day). Ingestion of large quantities of raw egg whites (∼20 eggs/day\sim 20\,\text{eggs/day}) causes deficiency because egg white avidin binds dietary biotin with high affinity, preventing intestinal absorption.

    • Vitamin B9B_9 (Folic Acid / Folate)
  • Active Coenzyme Form: Tetrahydrofolate (THF), produced by reduction of dietary folate via dihydrofolate reductase (DHFR).

Conversion of Folic Acid to THF and its Pathway Interactions

  • Biological Function: Serves as a carrier of one-carbon units (N10\text{N}^{10}-formyl THF, N5,N10\text{N}^5,\text{N}^{10}-methylene THF, N5\text{N}^5-methyl THF) essential for purine nucleotide synthesis, thymidine monophosphate (dTMP) synthesis, and amino acid interconversions.

  • Deficiency: Results in macrocytic megaloblastic anemia due to impaired DNA replication halting nuclear division in erythroblasts. Maternal deficiency during early pregnancy causes fetal neural tube defects (spina bifida and anencephaly). High-dose supplementation (UL=1 mg/day\text{UL} = 1\,mg/day) can mask the hematological manifestations of Vitamin B12B_{12} deficiency while allowing neurodegeneration to progress.

    • Vitamin B12B_{12} (Cobalamin)
  • Active Coenzyme Forms: Methylcobalamin and 5'-deoxyadenosylcobalamin.

Cobalamin Coenzyme Reactions

  • Biological Function:

    1. Methionine Synthase: Uses methylcobalamin to transfer a methyl group from N5\text{N}^5-methyl THF to homocysteine, generating methionine and releasing free THF.
    2. Methylmalonyl-CoA Mutase: Uses 5'-deoxyadenosylcobalamin to convert methylmalonyl-CoA to succinyl-CoA during odd-chain fatty acid and branched amino acid catabolism.
  • Absorption and Storage: Exclusively synthesized by microorganisms; absent from unfortified plant foods. Requires gastric Intrinsic Factor (IF) for absorption in the terminal ileum. Unlike other water-soluble vitamins, Vitamin B12B_{12} is stored in significant amounts in the liver (enough for 3 to 5 years).

  • Deficiency: Causes macrocytic megaloblastic anemia and progressive subacute combined degeneration of the spinal cord (due to accumulation of abnormal methylmalonyl-CoA damaging myelin). Pernicious anemia is an autoimmune disease destroying gastric parietal cells, eliminating Intrinsic Factor production.

    • Vitamin C (Ascorbic Acid)
  • Biological Function: Serves as a reducing agent (antioxidant) and coenzyme in hydroxylation reactions:

    1. Hydroxylation of prolyl and lysyl residues in procollagen (required for triple-helix stabilization).
    2. Reduction of non-heme iron from insoluble Fe3+\text{Fe}^{3+} to soluble Fe2+\text{Fe}^{2+} in the intestinal lumen, promoting iron absorption.
  • Scurvy: Severe deficiency manifesting as sore, spongy, bleeding gums, loose teeth, fragile capillary walls, cutaneous petechiae, impaired wound healing, and periosteal hematomas due to defective collagen cross-linking.

  • Toxicity: UL=2000 mg/day\text{UL} = 2000\,mg/day (vs. RDA=75 mg\text{RDA} = 75\,mg women, 90 mg90\,mg men). Excessive megadosing causes abdominal cramps, osmotic diarrhea, and increased risk of calcium oxalate kidney stone formation.

Fat-Soluble Vitamins

  • General Properties
    • Comprise Vitamins A, D, E, and K. Non-polar hydrophobic molecules stored in adipose tissue and the liver.
    • Require dietary lipid and emulsification by bile salts for micellar solubilization and absorption across intestinal enterocytes; incorporated into chylomicrons for transport.
    • Due to tissue storage capacity, fat-soluble vitamins accumulate over time, presenting a higher risk of hypervitaminosis toxicity compared to water-soluble vitamins. Deficiencies take longer to manifest.

Fat-Soluble Vitamins Hierarchy

  • Vitamin A (Retinoids and Carotenoids)
    • Active Forms:
    • Retinol: Preformed Vitamin A (stored as retinyl esters).
    • Retinal: Oxidized derivative essential for visual phototransduction.
    • Retinoic Acid: Ligand for nuclear retinoic acid receptors (RAR/RXR) regulating epithelial cell differentiation and gene expression.
    • β\beta-Carotene: Provitamin A carotenoid cleaved in the intestine to yield two molecules of retinal (1/121/12 the potency of preformed retinol).
    • Visual Cycle: All-trans retinol delivered to the retina is converted to 11-cis retinal. 11-cis retinal binds opsin in rod cells to form rhodopsin. Absorption of light induces photoisomerization of 11-cis retinal to all-trans retinal, triggering a nerve impulse sent to the visual cortex.

Vitamin A Absorption, Transport, and Visual Cycle

  • Deficiency: Manifests early as night blindness (nyctalopia). Severe deficiency leads to xerophthalmia (progressive corneal drying, keratinization, Bitot's spots, and permanent blindness) and impaired epithelial barrier immunity.
  • Toxicity and Teratogenesis: UL=3000 μg/day\text{UL} = 3000\,\mu g/day preformed retinol. Chronic toxicity causes dry fissured skin, hepatomegaly, hepatic cirrhosis, bone pain, and pseudotumor cerebri. Retinoids are highly teratogenic; high doses must be strictly avoided during pregnancy.
  • Transport and Storage: Retinol is absorbed in chylomicrons, stored as retinyl palmitate in hepatic stellate cells, and exported bound to Retinol-Binding Protein (RBP) and Transthyretin (TTR).

Vitamin A Transport Mechanisms

  • Vitamin D (Cholecalciferol / Calcitriol)
    • Active Form: 1,25-dihydroxycholecalciferol (1,25-diOH-D31,25\text{-diOH-D}_3 or Calcitriol).
    • Synthesis and Hydroxylation Activation:
    1. 7-Dehydrocholesterol in the skin undergoes photolysis by UV light to form Cholecalciferol (Vitamin D3\text{Vitamin D}_3).
    2. In the liver, 25-hydroxylase converts D3\text{D}_3 to Calcidiol (25-OH-D325\text{-OH-D}_3, main circulating storage form).
    3. In the kidney proximal tubules, 25-hydroxyvitamin D 1-α\alpha-hydroxylase converts calcidiol to active Calcitriol.
    • Regulation: 1-α\alpha-hydroxylase is up-regulated by Parathyroid Hormone (PTH) and hypophosphatemia, and down-regulated by high calcitriol levels.

Vitamin D Synthesis and Activation

  • Biological Function: Binds nuclear receptors in target tissues to increase plasma calcium and phosphate levels:

    • Intestine: Stimulates transcription of calbindin, enhancing intestinal calcium absorption.
    • Kidney: Enhances renal tubular reabsorption of calcium.
    • Bone: Works synergistically with PTH to stimulate osteoclastogenesis and bone resorption when plasma calcium is low.
  • Deficiency Disorders:

    • Rickets: Occurs in infants and children. Inadequate mineralization of newly formed bone matrix leads to unmineralized osteoid, widened epiphyseal growth plates, soft pliable bones, and bow-legged deformities.

    • Osteomalacia: Occurs in adults. Demineralization of pre-existing mature bone matrix leads to bone pain, muscle weakness, and pathological fractures.

    • Vitamin E (Tocopherols and Tocotrienols)

  • Active Form: α\alpha-Tocopherol (most biologically active form).

  • Biological Function: Lipophilic chain-breaking antioxidant. Prevents non-enzymatic lipid peroxidation of polyunsaturated fatty acids (PUFAs) in cellular membranes and protects LDL particles from oxidation. Active α\alpha-tocopherol is regenerated by reducing equivalents from Vitamin C.

  • Deficiency: Manifests as hemolytic anemia (due to oxidative fragility of red blood cell membranes), spinocerebellar ataxia, peripheral neuropathy, and loss of proprioception/vibratory sensation.

  • Toxicity: UL=1000 mg/day\text{UL} = 1000\,mg/day. High-dose supplementation interferes with Vitamin K-dependent blood clotting factor synthesis, enhancing the anti-coagulant effect of drugs like Warfarin.

    • Vitamin K (Phylloquinones, Menaquinones, Menadione)
  • Active Forms: Phylloquinone (K1\text{K}_1, plant origin), Menaquinone (K2\text{K}_2, synthesized by intestinal microbiota), Menadione (K3\text{K}_3, synthetic precursor).

  • Biological Function: Essential coenzyme for γ\gamma-glutamyl carboxylase, which post-translationally carboxylates specific glutamic acid residues to γ\gamma-carboxyglutamate (Gla) residues on precursor proteins.

Vitamin K Cycle and Warfarin Action

  • Target Gla Proteins: Blood clotting factors II (prothrombin), VII, IX, and X, as well as bone proteins (osteocalcin). Gla residues act as bidentate chelators that bind Ca2+Ca^{2+}, enabling factors to dock onto negatively charged phospholipid membranes of platelets.
  • Pharmacological Inhibition: Vitamin K Epoxide Reductase (VKOR) converts oxidized Vitamin K epoxide back to active hydroquinone. The anticoagulant Warfarin competitively inhibits VKOR, preventing clotting factor maturation.
  • Deficiency: Causes hemorrhagic disease with elevated prothrombin time (PT) and bleeding. Newborns are susceptible due to a sterile intestinal tract, low placental transfer, and low concentration in human milk; routine prophylactic Vitamin K injection is administered at birth.

Mineral Metabolism and Homeostasis

  • Mineral Classifications

    • Macrominerals: Daily dietary requirement >100 mg/day> 100\,mg/day (Calcium, Phosphorus, Magnesium, Sodium, Chloride, Potassium).
    • Microminerals (Trace): Requirement between 1 mg/day1\,mg/day and 100 mg/day100\,mg/day (Iron, Copper, Zinc, Chromium, Manganese, Fluorine).
    • Ultra-trace Minerals: Requirement <1 mg/day< 1\,mg/day (Iodine, Selenium, Molybdenum).
  • Macrominerals

    • Calcium (Ca2+Ca^{2+}):
    • Most abundant mineral in the body; 98%98\% is localized to skeletal bones and teeth as hydroxylapatite (Ca5[PO4]3OHCa_5[PO_4]_3OH).
    • Endocrine Regulation:
      • Parathyroid Hormone (PTH): Secreted by parathyroid glands in response to hypocalcemia. Increases bone resorption, increases renal calcium reabsorption, inhibits renal phosphate reabsorption, and stimulates renal 1-α\alpha-hydroxylase.
      • Calcitriol: Enhances intestinal calcium and phosphate absorption.
      • Calcitonin: Secreted by thyroid C-cells in response to hypercalcemia. Inhibits osteoclastic bone resorption and promotes renal excretion of calcium.
    • Phosphorus (PiP_i):
    • Majority (85%85\%) forms hydroxylapatite in bone; remainder acts as an intracellular buffer, component of ATP, nucleic acids, and phospholipids.
    • Deficiency: Hypophosphatemia occurs in refeeding syndrome (rapid carbohydrate refeeding in severely malnourished patients triggers insulin release, driving phosphate into cells for glycolysis, resulting in ATP depletion and cardiac arrest).
    • Magnesium (Mg2+Mg^{2+}):
    • Essential cofactor for all enzymes utilizing or synthesizing ATP (kinases, polymerases). 60%60\% stored in bone tissue.
    • Deficiency: Causes neuromuscular hyperexcitability, tetany, and cardiac arrhythmias. Intravenous MgSO4MgSO_4 is administered for eclampsia and preeclampsia.
    • Sodium (Na+Na^+) and Chloride (Cl−Cl^-):
    • Primary extracellular electrolytes regulating osmotic pressure and fluid balance. Na+Na^+ drives secondary active transport of glucose and amino acids in intestinal and renal epithelia.
    • Potassium (K+K^+):
    • Primary intracellular cation. Regulates resting membrane potential. Hyperkalemia or hypokalemia triggers fatal cardiac arrhythmias.
  • Microminerals

    • Copper (CuCu):
    • Essential catalytic cofactor for ferroxidases (ceruloplasmin, hephaestin), cytochrome c oxidase, lysyl oxidase, and superoxide dismutase.
    • Genetic Disorders of Copper Transport:

Comparison of Menkes and Wilson Disease Variables

  - *Menkes Disease*: X-linked recessive mutation in the *ATP7A* gene encoding a copper-transporting ATPase. Efflux of copper from enterocytes into blood is impaired, resulting in severe systemic copper deficiency, kinky hair, cerebral degeneration, and arterial tortuosity.
  - *Wilson Disease*: Autosomal recessive mutation in the *ATP7B* gene encoding a canalicular copper-transporting ATPase. Biliary copper excretion and ceruloplasmin incorporation are blocked, leading to toxic copper accumulation in the liver, brain (basal ganglia), cornea (**Kayser-Fleischer rings**), and kidneys. Treated with copper chelators (penicillamine).
  • Zinc (ZnZn): Structural constituent of zinc finger transcription factor domains and catalytic cofactor for over 300 enzymes (carbonic anhydrase, alkaline phosphatase). High dietary phytates inhibit intestinal zinc absorption.

  • Chromium (CrCr): Potentiates insulin signaling and glucose tolerance.

  • Fluorine (F−F^-): Replaces hydroxyl groups in dental enamel hydroxylapatite to form fluoroapatite, increasing resistance to acid-induced dental caries.

    • Ultra-trace Minerals
  • Iodine (II): Concentrated in the thyroid gland for synthesis of thyroid hormones (T3T_3 and T4T_4). Deficiency leads to goiter and hypothyroidism (maternal deficiency during gestation causes cretinism, characterized by severe intellectual disability and short stature).

  • Selenium (SeSe): Incorporated into 25 human selenoproteins as selenocysteine (e.g., glutathione peroxidase, thioredoxin reductase, deiodinases).

Iron Physiology, Transport, and Disorders

  • Biological Distribution and Function
    • Total body iron equals ∼4–5 g\sim 4\text{--}5\,g.
    • Distribution: Circulating erythrocyte hemoglobin contains ∼1800 mg\sim 1800\,mg; liver storage contains ∼1000 mg\sim 1000\,mg; reticuloendothelial macrophages hold ∼600 mg\sim 600\,mg; bone marrow holds ∼300 mg\sim 300\,mg; muscle myoglobin holds ∼300 mg\sim 300\,mg; plasma transferrin holds ∼3 mg\sim 3\,mg.
    • Daily physiological iron loss is low (1–2 mg/day1\text{--}2\,mg/day through sloughed enterocytes, desquamation, or menstruation).

Total Body Iron Distribution

  • Dietary Forms and Intestinal Absorption
    • Heme Iron: Found in red meat, poultry, and fish. Highly bioavailable (15–35%15\text{--}35\% absorbed). Imported intact across enterocyte apical membranes via Heme Carrier Protein (HCP) and broken down by heme oxygenase to release free Fe2+\text{Fe}^{2+}.
    • Non-Heme Iron: Found in plant sources (spinach, lentils). Lower bioavailability (10–20%10\text{--}20\% absorbed). Must be reduced from ferric (Fe3+\text{Fe}^{3+}) to ferrous (Fe2+\text{Fe}^{2+}) iron by apical Duodenal Cytochrome B (DCYTB) ferrireductase before transport through Divalent Metal Transporter 1 (DMT-1).
    • Absorption Enhancers: Ascorbic acid (Vitamin C), organic acids, and animal tissue.
    • Absorption Inhibitors: Phytates, polyphenols, tannates, dietary fiber, calcium, oxalates, and antacids.
    • Intracellular iron is stored bound within Ferritin as ferric (Fe3+\text{Fe}^{3+}) iron (one ferritin complex holds up to 4500 Fe3+\text{Fe}^{3+} atoms).

Enterocyte Iron Absorption Mechanism

  • Systemic Export, Transport, and Cellular Import

    • Ferroportin: The only known cellular iron exporter, located on the basolateral membrane of enterocytes, macrophages, and hepatocytes.
    • Hephaestin (HEPH): Basolateral ferroxidase that re-oxidizes exported Fe2+\text{Fe}^{2+} to Fe3+\text{Fe}^{3+}, allowing binding to plasma Transferrin (Tf). Transferrin carries up to two Fe3+\text{Fe}^{3+} ions in circulation.
    • Hepcidin: Master systemic regulator produced by hepatocytes. Binds ferroportin, inducing its phosphorylation, endocytosis, and lysosomal degradation—blocking intestinal absorption and macrophage release.
    • Up-regulated by systemic iron overload, inflammation, and infection (via IL-6).
    • Down-regulated by erythropoietin and erythroferrone (released by erythroblasts during high erythropoiesis).
    • Cellular Import: Tf-Fe3+\text{Tf-Fe}^{3+} complex binds cell-surface Transferrin Receptor 1 (TfR1) on erythroblasts or hepatocytes, undergoing receptor-mediated endocytosis. Endosomal acidification releases Fe3+\text{Fe}^{3+}, which is reduced and transported into the cytoplasm via DMT-1.
  • Cellular Iron Homeostasis via the IRE/IRP System

    • Governed post-transcriptionally by Iron Regulatory Proteins (IRP1/IRP2) binding Iron-Responsive Elements (IREs) stem-loop structures on target mRNAs:
    • Low Cellular Iron: IRPs lack iron and bind IREs. Binding to the 3′3'\text{-UTR} of TfR mRNA stabilizes the transcript, increasing TfR synthesis and cellular iron uptake. Binding to the 5′5'\text{-UTR} of Ferritin mRNA blocks translation, decreasing iron storage.
    • High Cellular Iron: Iron binds IRPs, causing conformational change or degradation. Unbound TfR mRNA 3′3'\text{-UTR} is degraded; unbound Ferritin mRNA 5′5'\text{-UTR} is translated.

Cellular Iron Regulation via IRE and IRP

  • Iron Disorders and Diagnostics

Stages of Iron Deficiency Table

  • Iron Deficiency Anemia (Stage 3): Depletion of iron stores leads to microcytic hypochromic red blood cells. Characterized by low serum ferritin, low serum iron, high Total Iron-Binding Capacity (TIBC), low Transferrin Saturation (TSAT), and low hemoglobin.
  • Anemia of Chronic Disease: Driven by chronic inflammatory states where elevated IL-6 induces high hepcidin levels. Ferroportin is degraded, trapping iron inside macrophages and hepatocytes. Serum iron drops despite adequate or high ferritin stores.
  • Hereditary Hemochromatosis: Autosomal recessive disorder caused by mutations in HFE, TfR2, or HAMP (hepcidin). Low hepcidin activity causes unrestrained intestinal iron absorption and macrophage export. Toxic iron deposition (Fe2+\text{Fe}^{2+} generates ROS via Fenton reactions) damages hepatocytes (cirrhosis), pancreas (bronze diabetes), and heart (cardiomyopathy). Managed via therapeutic phlebotomy.

Alcohol Absorption, Metabolism, and Pathophysiology

  • Standard Intake Definitions and Absorption Physiology

    • Ethanol (CH3CH2OH\text{CH}_3\text{CH}_2\text{OH}) is a small water-soluble molecule that diffuses across lipid membranes. A standard drink contains ∼14 g\sim 14\,g of pure ethanol (12 oz12\,oz beer at 5%5\%, 5 oz5\,oz wine at 12%12\%, 1.5 oz1.5\,oz distilled spirits at 40%40\%).
    • Absorption: Rapidly absorbed along the GI tract (∼20%\sim 20\% stomach, ∼80%\sim 80\% small intestine). Gastric emptying rate determines overall absorption kinetics; food delays gastric emptying and slows absorption. High-proof spirits (40%40\%) delay gastric emptying, whereas carbonated alcoholic drinks increase absorption rate.
    • Sex Differences: Women display higher peak Blood Alcohol Concentrations (BAC) than men for an equivalent dose due to lower total body water volume, higher body fat percentage, and reduced gastric Alcohol Dehydrogenase (ADH) activity.
  • Enzymatic Oxidation Pathways

Summary of Alcohol Oxidation in Stomach and Liver

  1. Gastric First-Pass Metabolism: Gastric ADH enzymes oxidize a portion of ingested alcohol in the stomach mucosa before absorption, reducing systemic bioavailability. Gastritis or chronic heavy drinking degrades gastric ADH activity.
  2. Hepatic Alcohol Dehydrogenase (ADH) Pathway: Primary cytosolic pathway (∼90%\sim 90\% of ethanol metabolism). Low KmK_m for ethanol (1–10 mg%1\text{--}10\,mg\%):      CH3CH2OH+NAD+⇌CH3CHO+NADH+H+\text{CH}_3\text{CH}_2\text{OH} + \text{NAD}^+ \rightleftharpoons \text{CH}_3\text{CHO} + \text{NADH} + \text{H}^+
  3. Microsomal Ethanol Oxidizing System (MEOS): Located in the smooth endoplasmic reticulum, catalyzed by CYP2E1 (Cytochrome P450 2E1). High KmK_m for ethanol (50–80 mg%50\text{--}80\,mg\%); plays an increasing role at elevated BACs:      CH3CH2OH+NADPH+H++O2⇌CH3CHO+NADP++2 H2O\text{CH}_3\text{CH}_2\text{OH} + \text{NADPH} + \text{H}^+ + \text{O}_2 \rightleftharpoons \text{CH}_3\text{CHO} + \text{NADP}^+ + 2\,\text{H}_2\text{O}
    • Induction and Drug Toxicity: Chronic heavy alcohol intake induces CYP2E1 transcription. Induced CYP2E1 metabolizes acetaminophen into the hepatotoxic radical NAPQI, causing acute liver failure at lower doses.
  4. Aldehyde Dehydrogenase (ALDH) Pathway: Mitochondrial ALDH2 converts toxic acetaldehyde to acetate:      CH3CHO+NAD++H2O⇌CH3COOH+NADH+H+\text{CH}_3\text{CHO} + \text{NAD}^+ + \text{H}_2\text{O} \rightleftharpoons \text{CH}_3\text{COOH} + \text{NADH} + \text{H}^+
    • Alcohol Flush Reaction: Inactive ALDH2 gene variants cause accumulation of toxic acetaldehyde, triggering facial flushing, tachycardia, and nausea.
    • Disulfiram (Antabuse): Pharmacologically inhibits ALDH, causing severe acetaldehyde accumulation to deter alcohol consumption.
  • Pathophysiological Mechanisms of Liver Damage

Pathological Mechanisms of Alcohol Metabolism

  • Elevation of Hepatic NADH/NAD+ Ratio:

    • Lactic Acidosis and Hypoglycemia: High NADH/NAD+\text{NADH/NAD}^+ shifts the lactate dehydrogenase reaction toward lactate, suppressing gluconeogenesis from pyruvate and causing lactic acidosis and fasting hypoglycemia.
    • Hepatic Steatosis: High NADH/NAD+\text{NADH/NAD}^+ inhibits β\beta-oxidation of fatty acids and suppresses the TCA cycle. Unoxidized fatty acids are esterified into triglycerides, causing fat accumulation in hepatocytes (steatosis), progressing to alcoholic hepatitis, hepatic fibrosis, and cirrhosis.
    • ATP Depletion: TCA cycle inhibition disrupts oxidative phosphorylation, leading to cellular ATP depletion and hepatocyte necrosis.
  • Acetaldehyde Toxicity: Acetaldehyde forms covalent adducts with proteins and DNA, generating reactive oxygen species (ROS), impairing protein secretion, and driving lipid peroxidation and hepatocarcinogenesis.

    • Associated Nutritional Deficiencies
  • Thiamine (Vitamin B1B_1) Deficiency: Caused by poor intake, damaged intestinal absorption, and impaired hepatic storage. Triggers Wernicke-Korsakoff Syndrome.

  • Folate (Vitamin B9B_9) Deficiency: Caused by malabsorption and increased renal clearance; leads to macrocytic megaloblastic anemia.

  • Pyridoxine (Vitamin B6B_6) Deficiency: Leads to impaired transaminase activity and anemia.

Regulation of the Cell Cycle

  • Phases of the Eukaryotic Cell Cycle

Phases of the Cell Cycle

  • Interphase: Occupies the vast majority of cell life:
    • G1G_1 Phase (First Gap): Active cellular growth, RNA/protein synthesis, organelle duplication, and metabolic expansion. The most variable phase in duration.
    • G0G_0 Phase: Quiescent, non-dividing state entered from G1G_1. Can be reversible (quiescent hepatocytes) or permanent post-mitotic (neurons).
    • Restriction Point: Critical checkpoint in late G1G_1. Once passed, the cell is irrevocably committed to completing DNA replication and division without requiring external growth factors.
    • SS Phase (Synthesis): Nuclear DNA replication occurs; each of the 46 chromosomes is duplicated to yield sister chromatids bound at centromeres. Lasts ∼6 hours\sim 6\,\text{hours}.
    • G2G_2 Phase (Second Gap): Safety gap ensuring complete DNA replication and checking genomic integrity before nuclear division. Lasts ∼4 hours\sim 4\,\text{hours}.
  • Mitosis (MM Phase): Nuclear division lasting ∼1 hour\sim 1\,\text{hour}, divided into five sequential stages:

Stages of Mitosis and Cytokinesis

1. *Prophase*: Chromatin condenses into visible chromosomes; kinetochores assemble at centromeres; nucleolus disassembles; centrosomes migrate to opposite poles to form the mitotic spindle.
2. *Prometaphase*: Nuclear envelope breaks down; spindle microtubules capture kinetochores.
3. *Metaphase*: Chromosomes align along the equatorial metaphase plate.
4. *Anaphase*: Centromeres cleave; sister chromatids separate and move toward opposite spindle poles.
5. *Telophase*: Nuclear envelopes reform around daughter nuclei; chromatids decondense; nucleoli reappear.
  • Cytokinesis: Cleavage furrow forms via contraction of an equatorial actin-myosin microfilament ring, pinching the cytoplasm to yield two genetically identical daughter cells.

    • Cyclin and Cyclin-Dependent Kinase (CDK) Machinery

Cell Cycle Function of Cyclins and CDKs Table

  • CDKs are serine/threonine protein kinases present in constant intracellular amounts. Their catalytic activity requires binding to regulatory cyclin subunits, whose levels oscillate throughout the cell cycle.

  • Phase-Specific Complexes:

    • G1G_1 Phase Progression: Cyclin D (D1, D2, D3) complexes with CDK4 or CDK6 to drive the cell past the restriction point.

    • G1/SG_1/S Transition and SS Phase Initiation: Cyclin E complexes with CDK2 to initiate DNA replication.

    • SS Phase Progression: Cyclin A complexes with CDK2.

    • G2/MG_2/M Transition: Cyclin B complexes with CDK1 (CDC2) to initiate mitosis.

    • Checkpoint Mechanisms and Tumor Suppressors

  • Retinoblastoma Protein (RB) and the G1/SG_1/S Checkpoint:

RB Phosphorylation and E2F Regulation

- In resting cells, unphosphorylated or hypophosphorylated RB protein binds to the **E2F** transcription factor, inhibiting gene expression needed for SS phase.
- Growth factor signaling activates Cyclin D-CDK4/6 complexes, which hyperphosphorylate RB. Hyperphosphorylated RB dissociates from E2F, releasing E2F to transcribe genes for SS phase entry (Cyclin E, DNA polymerase).
  • p53 and the p21CIP1p21^{CIP1} DNA Damage Response:

p53 DNA Damage Checkpoint Pathway

- DNA double-strand breaks activate protein kinases (ATM/ATR) that phosphorylate and stabilize **p53**.
- Active p53 acts as a transcription factor for **p21CIP1p21^{CIP1}** (a CDK inhibitor), which binds and inhibits Cyclin-CDK complexes, arresting the cell cycle in G1G_1 to allow DNA repair.
- If damage is irreparable, p53 transcribes pro-apoptotic genes (Bax) to trigger programmed cell death.
  • Pharmacological Cell Cycle Interventions
    • Antimetabolites (e.g., Methotrexate, 5-Fluorouracil): Act specifically in SS phase by competing with natural nucleotide precursors to inhibit purine/pyrimidine synthesis or incorporate into replicating DNA.
    • Anticancer Antibiotics (e.g., Bleomycin): Induce strand breaks causing accumulation of cells in G2G_2 phase.
    • Mitotic Spindle Poisons: Act specifically during metaphase (MM phase):
    • Vinca Alkaloids (Vincristine, Vinblastine): Bind free tubulin dimers, preventing microtubule polymerization.
    • Taxanes (Paclitaxel/Taxol): Hyper-stabilize polymerized microtubules, preventing spindle disassembly.

Regulation of Apoptosis

  • Apoptosis vs. Necrosis

Comparison of Necrosis and Apoptosis

  • Necrosis: Passive, pathological cell death resulting from acute injury. Involves groups of adjacent cells. Cell membranes rupture, spilling lysosomal enzymes and cellular debris into surrounding tissue, eliciting severe inflammatory responses.

  • Apoptosis: Active, energy (ATP)-dependent, highly regulated physiological programmed cell death affecting individual isolated cells. Membrane integrity is maintained without inducing inflammation.

    • Biochemical and Morphological Events
  • Activation of ROCK1 kinase reorganizes the actin cytoskeleton, generating plasma membrane protrusions (blebbing) and apoptotic bodies.

  • Activation of scramblase flips phosphatidylserine from the inner cytoplasmic leaflet to the outer extracellular leaflet.

  • Externalized phosphatidylserine acts as an "eat-me" signal recognized by phagocytic macrophages, which engulf apoptotic bodies and release anti-inflammatory cytokines (IL-10, TGF-β\beta).

  • Caspase-Activated DNase (CAD) (released upon caspase cleavage of its inhibitor ICAD/DFF45) cleaves inter-nucleosomal linker DNA into regular fragments of ∼180–200 bp\sim 180\text{--}200\,bp multiples, displaying a classic DNA ladder on gel electrophoresis.

    • The Intrinsic (Mitochondrial) Apoptotic Pathway
  • Triggered by internal cellular stress, severe DNA damage, or deprivation of growth factors.

  • p53 or cellular stress transcribes pro-apoptotic Bax and Bak (Bcl-2 family), which translocate to the outer mitochondrial membrane and form pores.

  • Cytochrome c leaks from the mitochondrial intermembrane space into the cytosol.

  • Cytosolic Cytochrome c binds Apaf-1 (Apoptotic Protease Activating Factor-1) in the presence of dATP/ATP, assembling a heptameric wheel-like complex called the Apoptosome.

Apoptosome Formation Mechanism

  • The apoptosome recruits and cleaves inactive pro-caspase-9 to form active Caspase-9 (initiator caspase), which then cleaves and activates downstream executioner caspases (Caspases-3, 6, 7).

    • The Extrinsic (Death Receptor) Apoptotic Pathway
  • Triggered by external extracellular signals binding cell-surface death receptors belonging to the Tumor Necrosis Factor Receptor (TNFR) superfamily (e.g., Fas / CD95 bound by FasL / CD178 on cytotoxic T-lymphocytes).

Extrinsic Death Receptor Signaling Pathway

  • Ligand binding causes receptor trimerization and brings cytoplasmic Death Domains (DD) together.

  • Adaptor proteins (FADD) containing Death Domains dock onto the receptor, forming the DISC (Death-Inducing Signaling Complex).

  • DISC recruits pro-caspase-8 via Death Effector Domains (DED), cleaving it to form active Caspase-8 (initiator caspase).

  • Active Caspase-8 directly activates executioner Caspase-3, or cleaves the BH3-only protein Bid to tBid, which translocates to mitochondria to engage the intrinsic pathway (cross-talk).

    • Caspase Family Proteases and Bcl-2 Family Proteins
  • Caspases: Cysteine proteases that cleave peptide bonds C-terminal to aspartic acid residues:

    • Initiator Caspases: Caspases-2, 8, 9, 10 (contain long CARD or DED N-terminal pro-domains).
    • Executioner (Effector) Caspases: Caspases-3, 6, 7 (cleave nuclear lamins, PARP, and ICAD).
    • Non-Apoptotic Caspases: Caspase-1 (IL-1β\beta processing), Caspases-4, 5 (inflammation), Caspase-14 (keratinocyte development).
  • Bcl-2 Family Regulators:

    • Pro-Survival (Anti-Apoptotic): Bcl-2, Bcl-xL (bind and sequester Bax/Bak to preserve mitochondrial integrity).
    • Pro-Apoptotic (Pore-Forming): Bax, Bak.
    • Pro-Apoptotic (BH3-Only Sensitizers/Activators): Bid, Bad, Bim.

Molecular Basis of Cancer, Progression, and Therapy

  • Neoplastic Definitions and Classification

    • Neoplasia: Abnormal, uncoordinated cellular proliferation escaping normal homeostatic growth controls.
    • Benign Neoplasms: Encapsulated, localized, slow-growing masses incapable of invading adjacent basement membranes or metastasizing.
    • Malignant Neoplasms (Cancer): Anaplastic masses capable of local tissue invasion and distant hematogenous or lymphatic metastasis.
    • Major Histological Taxonomies:
    • Carcinoma: Malignancy of epithelial origin (covers internal/external body surfaces). Includes Adenocarcinoma (glandular tissue), Basal Cell Carcinoma, and Squamous Cell Carcinoma. Pre-invasive lesions bounded by intact basement membranes are termed Carcinoma in situ.
    • Sarcoma: Malignancy of mesenchymal origin (bone, cartilage, fat, smooth/skeletal muscle, blood vessels). Examples: Osteosarcoma, Liposarcoma, Myosarcoma.
    • Nervous System Cancers: Derived from neuroectodermal tissues. Includes adult Gliomas (Glioblastoma, Oligodendroglioma) and pediatric tumors (Neuroblastoma, Medulloblastoma).
    • Hematologic Cancers: Proliferations of hematopoietic cells. Includes Leukemia (originates in bone marrow; AML, CML, ALL, CLL), Lymphoma (originates in lymphatic tissues; Hodgkin and Non-Hodgkin), and Multiple Myeloma (plasma cell proliferation).
  • Multi-Step Carcinogenesis and Genetic Mutations

    • Carcinogenesis proceeds sequentially through three defined phases:
    1. Initiation: An irreversible somatic DNA mutation caused by a genotoxic carcinogen (chemical, radiation, viral) affecting a proto-oncogene or tumor suppressor gene.
    2. Promotion: Selective clonal expansion of initiated pre-neoplastic cells driven by chronic proliferative stimuli (promoters, inflammation, hormones).
    3. Progression: Acquisition of additional somatic mutations, karyotypic instability, and genomic heterogeneity yielding an aggressive malignant tumor.
    • Major Gene Classes Mutated:
    • Proto-oncogenes: Normal genes promoting cell growth. Gain-of-function mutations convert them into hyperactive oncogenes (e.g., RAS, PI3K, MYC).
    • Tumor Suppressor Genes: Normal brake genes inhibiting proliferation or driving apoptosis. Loss-of-function mutations in both alleles trigger transformation (e.g., TP53, RB, APC).
    • DNA Repair Genes: Fix replication errors. Mutations cause genomic instability (e.g., BRCA1/2 in double-strand break repair; MSH2/MLH1 in mismatch repair).
  • Hallmarks of Cancer

    • Biological capabilities acquired by mutating cells during tumor evolution:
    1. Sustaining Proliferative Signaling: Constitutive activation of growth pathways (PI3K/Akt/mTOR, Ras/MAPK) independent of external growth factors.
    2. Evading Growth Suppressors: Inactivation of RB and p53 checkpoint pathways.
    3. Resisting Cell Death: Up-regulation of Bcl-2 and loss of p53 function.
    4. Enabling Replicative Immortality: Ectopic expression of telomerase to prevent telomere shortening and replicative senescence.
    5. Inducing Angiogenesis: Secretion of Vascular Endothelial Growth Factor (VEGF) to sprout host blood vessels into hypoxic tumor centers.
    6. Activating Invasion and Metastasis: Degradation of extracellular matrix (ECM) proteins via secretion of Matrix Metalloproteinases (MMPs).
  • Tumor Metabolism: The Warburg Effect

    • Cancer cells reprogram energy metabolism, favoring high rates of aerobic glycolysis to convert glucose into lactate even when oxygen is abundant.

The Warburg Effect Metabolic Pathway

  • Driven by up-regulation of GLUT1/GLUT3 glucose transporters and Lactate Dehydrogenase (LDH).

  • Advantages for Malignancy:

    1. Glycolytic intermediates are diverted into anabolic side branches (Pentose Phosphate Pathway via G6PD) to synthesize nucleotides, lipids, and amino acids for rapid cell division.
    2. Secreted lactate acidifies the tumor microenvironment, activating MMPs to facilitate invasion and inducing HIF-1α\alpha and VEGF for angiogenesis.
    3. G6PD activity generates NADPH, required by glutathione reductase to maintain reduced Glutathione (GSH) reserves against ROS.
  • Positron Emission Tomography (PET Scan): Exploits the Warburg effect by injecting radioactive \text{^{18}F}--Fluorodeoxyglucose (FDG). FDG is imported via GLUT transporters into avid cancer cells and phosphorylated by hexokinase, becoming trapped to visualize primary tumors and metastases.

    • Cancer Grading, Staging, and the Metastatic Cascade
  • Tumor Grade: Microscopic evaluation of cell differentiation (Grade 1 = well-differentiated, low-grade; Grade 4 = undifferentiated, highly aggressive).

  • Tumor Staging (TNM System): Describes anatomical tumor extent:

    • T: Size and invasion depth of primary tumor.
    • N: Extent of regional lymph node metastasis.
    • M: Presence or absence of distant metastasis (M0M_0 = no distant spread; M1M_1 = distant metastasis present / Stage IV).

The Metastatic Cascade Overview

  • The Metastatic Cascade (5 Sequential Steps):

    1. Invasion: Cancer cells break through the basement membrane and degrade local ECM using MMPs.
    2. Intravasation: Migrating tumor cells penetrate blood or lymphatic vessel walls to enter circulation.
    3. Circulation: Cells travel through the vascular network; surviving cells interact with platelets to evade immune destruction.
    4. Extravasation: Circulating tumor cells adhere to endothelial walls in distant capillary beds and exit into host parenchyma.
    5. Colonization: Tumor cells adapt to the secondary microenvironment, surviving pre-metastatic niches to proliferate into metastatic lesions.
    • Cancer Mortality Drivers and Therapeutic Modalities
  • Major Causes of Death: Metastatic organ destruction, multi-drug resistance (∼90%\sim 90\% of deaths), opportunist infections, and Cachexia (severe progressive involuntary muscle protein wasting and adipose destruction seen in advanced cancer patients, responsible for ∼20%\sim 20\% of solid tumor deaths).

  • Therapeutic Classification:

Methods of Cancer Therapy

- **Local Modalities**:
  - *Surgery*: En-bloc surgical resection of primary tumor and regional lymph nodes; effective for localized primary solid tumors.
  - *Radiation Therapy*: Uses high-energy ionizing radiation to induce fatal DNA double-strand breaks in tumor cells (delivered externally or via internal brachytherapy implants).
- **Systemic Modalities**:
  - *Chemotherapy*: Cytotoxic drugs affecting rapidly dividing cells. Includes cell-cycle specific agents (antimetabolites like 5-FU; mitotic inhibitors like vincristine and paclitaxel) and non-phase specific agents (alkylating agents; anthracyclines inhibiting topoisomerase II).
  - *Hormone Therapy*: Blocks hormone production or hormone receptor signaling in hormone-dependent malignancies (e.g., Tamoxifen or aromatase inhibitors in estrogen-receptor positive breast cancer; androgen deprivation therapy in prostate cancer).
  - *Targeted Therapy*: Monoclonal antibodies or small-molecule inhibitors engineered against specific molecular hallmarks (e.g., **Bevacizumab / Avastin** targeting VEGF to block angiogenesis; **Trastuzumab / Herceptin** targeting overexpressed HER2 in breast cancer).
  - *Immunotherapy*: Re-engages host immune responses against tumors. Includes **Immune Checkpoint Inhibitors** (anti-PD-1 / anti-PD-L1 antibodies) and **CAR T-Cell Therapy** (patient T-cells genetically engineered with chimeric antigen receptors targeting tumor antigens).
- **Mechanisms of Drug Resistance**: Overexpression of ATP-Binding Cassette (ABC) efflux transporters (e.g., P-glycoprotein) that actively pump chemotherapeutic agents out of cancer cells.